Actively Recruiting
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Led by Ruijin Hospital · Updated on 2023-06-12
332
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma
CONDITIONS
Official Title
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
- No prior treatment for follicular lymphoma
- Age 18 years or older
- Confirmed need for treatment
- Measurable lesion visible on CT or PET-CT before treatment
- Suitable for GR, GB, or GCHOP treatment regimens
- Provided informed consent
You will not qualify if you...
- Transformed follicular lymphoma or grade 3B follicular lymphoma
- Positive tests for HBsAg and/or HBcAb with HBV DNA titer; positive HCV antibody with HCV-RNA; or HIV positive
- Involvement of central nervous system or meninges
- Any drug contraindication to planned treatment
- Deemed unsuitable for the study by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Weili Zhao, +862164370045
CONTACT
P
Pengpeng Xu, PhD，MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here